http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2871092-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43426d588f25e8a725e88790fa9e416b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-595 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-26 |
| filingDate | 2011-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c99d87f32b942ebc1c7c3b666621af73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_259e66de8a32e6af316f78a6f0e0ccc6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c199bbbbe6a082661c35548d861f6a1d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa0955bc069aa928a1ee18f4e03287a6 |
| publicationDate | 2021-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2871092-T3 |
| titleOfInvention | Methods and compositions for the therapy of liver cancer |
| abstract | Monoclonal antibody that specifically binds to human progastrin (hPG) for use in a method of treating liver cancer or preventing recurrence of liver cancer, wherein said anti-hPG monoclonal antibody comprises VL CDRs and VH having sequences selected from one of the following groups of VL and VH CDR sequences: (i) VH CDR1.3 comprising the amino acid sequence of SEQ ID No. 1, VH CDR 2.3 comprising the amino acid sequence of SEQ ID No. 2, VH CDR 3.3 comprising the amino acid sequence of SEQ ID No. 3, VL CDR 1.3 comprising the amino acid sequence of SEQ ID No. 4, VL CDR 2.3 comprising the amino acid sequence of SEQ ID No. 5 , and VL CDR 3.3 comprising the amino acid sequence of SEQ ID NO: 6; (ii) VH CDR1.8 comprising the amino acid sequence of SEQ ID No. 37, VH CDR 2.8 comprising the amino acid sequence of SEQ ID No. 41, VH CDR 3.8 comprising the amino acid sequence of SEQ ID No. 45, VL CDR 1.8 comprising the amino acid sequence of SEQ ID No. 49, VL CDR 2.8 comprising the amino acid sequence of SEQ ID No. 52, and VL CDR 3.8 comprising the amino acid sequence of SEQ ID No. 55; (iii) VH CDR 1.13 comprising the amino acid sequence of SEQ ID No. 38, VH CDR 2.13 comprising the amino acid sequence of SEQ ID No. 42, VH CDR 3.13 comprising the amino acid sequence of SEQ ID No. 46, VL CDR 1.13 comprising the amino acid sequence of SEQ ID NO: 50, VL CDR |
| priorityDate | 2010-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 490.